TABLE 5.

Risk of neuropsychiatric events (NPEs) in relation to leukotriene receptor antagonist (LTRA) use in patients with asthma or allergic rhinitis according to type of NPE: cognitive, movement and personality disorders

	Cognitive disorder				Movement disorder				Personality disorder
	Events (n)	Person-years	IRR (95% CI)	p-value	Events (n)	Person-years	IRR (95% CI)	p-value	Events (n)	Person-years	IRR (95% CI)	p-value
Unexposed	1366	3205.13	1		798	1656.32	1		251	501.22	1
Exposed	55	171.90	0.75 (0.56–0.98)	0.045	30	65.86	1.18 (0.78–1.71)	0.410	9	20.74	1.05 (0.48–2.03)	0.883
Time since initiation of LTRA (days)
1–3	12	47.55	0.6 (0.32–1.01)	0.079	4	16.96	0.58 (0.18–1.35)	0.274	2	5.24	0.86 (0.21–3.49)	0.830
4–7	12	26.37	1.08 (0.57–1.82)	0.801	9	8.85	2.51 (1.19–4.60)	0.007	1	3.13	0.76 (0.10–5.45)	0.782
8–14	9	29.10	0.73 (0.35–1.32)	0.344	6	8.71	1.7 (0.67–3.50)	0.202	4	3.16	2.99 (1.08–8.22)	0.0344
15–30	7	33.44	0.48 (0.21–0.94)	0.057	5	10.94	1.14 (0.41–2.51)	0.768	1	3.36	0.71 (0.10–5.16)	0.735
31–90	12	27.18	1.02 (0.54–1.75)	0.950	3	12.44	0.66 (0.16–1.76)	0.478	1	3.60	0.65 (0.09–4.82)	0.673
>90	3	8.27	0.89 (0.21–2.46)	0.841	3	7.96	1.16 (0.27–3.48)	0.810	0	2.24	NA	NA

IRR: incidence rate ratio.